<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520180</url>
  </required_header>
  <id_info>
    <org_study_id>G-IC-001</org_study_id>
    <nct_id>NCT02520180</nct_id>
  </id_info>
  <brief_title>Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)</brief_title>
  <official_title>A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk™ Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk™ Stent System) for the Treatment of Atherosclerotic Lesion(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm,
      non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a
      &quot;real world, all comers&quot; study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: to compare the MicroPort Medical (Group) Co., Ltd Firehawk™cobalt chromium
      coronary stent ( rapamycin target eluting ) system with abluminal grooves containing a
      biodegradable polymer with the Abbott XIENCE family EES (Everolimus-Eluting stent) system
      with respect to cardiac death, myocardial infarction (not clearly attributable to a
      non-target vessel), Target Lesion Revascularization at 1 year in a &quot;real world&quot; patient
      population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>13 months</time_frame>
    <description>In-stent late loss at 13 months post-procedure as measured by quantitative coronary angiography (QCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent struth Neointimal thickness</measure>
    <time_frame>3 months</time_frame>
    <description>stent struth Neointimal thickness at 3 months measured by Optical Coherence Tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1656</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Firehawk™ stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MicroPort Firehawk™ stent system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience family Everolimus-Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abbott Xience family Everolimus-Eluting Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Firehawk™ stent system</intervention_name>
    <description>MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent</description>
    <arm_group_label>Firehawk™ stent system</arm_group_label>
    <other_name>MicroPort Firehawk™ rapamycin target eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abbott Xience family Everolimus-Eluting Stent</intervention_name>
    <description>Abbott Xience family Everolimus-Eluting Stent</description>
    <arm_group_label>Xience family Everolimus-Eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimal age 18 years

          -  Symptomatic coronary artery disease

          -  Patient acceptable candidate for treatment with drug eluting stent in accordance with
             applicable guidelines

          -  Presence of one or more coronary artery stenosis &gt;50% with reference diameter
             2.25-4.0mm which can be covered by one or multiple stents

          -  Patient indication, lesion length and vessel diameter according to 'Instructions for
             Use' of study stents

          -  Patient is willing and able to cooperate with study procedures and required follow up
             visits and patient or legal representative has been informed and agrees by signing EC
             approved written informed consent

        Exclusion Criteria:

          -  Women of childbearing potential who do not have a negative pregnancy test within 7
             days before procedure and women who are lactating

          -  Known intolerance to aspirin, clopidogrel or ticlopidin, heparin, cobalt, nickel,
             chromium, molybdenum, polymer coatings, Sirolimus, Everolimus, or contrast material

          -  Participating in other trial before reaching primary endpoint

          -  Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained
             throughout the peri-surgical period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wijns, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VZW Cardiovascular Research Center Aalst</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Baumbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Heart Institute/University Hospitals Bristol NHS Foundation Trust,UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Lansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Cardiovascular Research Group,USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Zheng, MD</last_name>
    <email>mzheng@microport.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene Holmvang, MD</last_name>
      <email>Lene.Holmvang@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Holmvang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

